Retrospective analysis of the impact of kidney function on the outcomes of first autografts for de novo myeloma patients in the era of novel agentsLajos Flóró, Stephen Schey, Ιωάννα Λαζανά et al.|Clinical Lymphoma Myeloma & Leukemia|2015Cited by 1
Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatmentJ. Waters, Matthew Streetly, Douglas Gunning et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 1
P-393 A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London retrospectiveDogan Yildiz, Arief Gunawan, Sajitha Sachchithanantham et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0